Product
[203Pb]VMT-alpha-NET
2 clinical trials
8 indications
Indication
Somatostatin Receptor PositiveIndication
Gastrointestinal Neuroendocrine TumorsIndication
PheochromocytomaIndication
ParagangliomasIndication
Pheochromocytoma/ParagangliomasIndication
Small Cell Lung CancerIndication
Kidney CancerIndication
Head and Neck TumorsClinical trial
Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand TherapyStatus: Not yet recruiting, Estimated PCD: 2029-07-01
Clinical trial
Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersStatus: Not yet recruiting, Estimated PCD: 2029-01-01